Holen Sie sich die Stockscreener-App
8.29
7.79%
-0.70
Handel nachbörslich:
8.28
-0.010
-0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.99
Offen:
$9.08
24-Stunden-Volumen:
27.70M
Relative Volume:
1.67
Marktkapitalisierung:
$3.76B
Einnahmen:
$285.55M
Nettoeinkommen (Verlust:
$-353.86M
KGV:
-8.7254
EPS:
-0.9501
Netto-Cashflow:
$-305.02M
1W Leistung:
+18.77%
1M Leistung:
+51.28%
6M Leistung:
+188.85%
1J Leistung:
+226.38%
1-Tages-Spanne:
$8.145
$9.30
1-Wochen-Bereich:
$6.7031
$9.36
52-Wochen-Spanne:
$1.76
$9.36
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
8.29 | 4.07B | 285.55M | -353.86M | -305.02M | -0.9501 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Hochstufung | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2025-05-12 | Herabstufung | Truist | Buy → Hold |
| 2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Biotech company Iovance grants 20 new employees options with an $8.99 exercise price - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.8%Here's Why - MarketBeat
IOVA Stock Pulls Back As Biotech Momentum Cools - StocksToTrade
UBS Lifts Iovance Biotherapeutics Price Target as Cancer Drug Sales Top Expectations - TIKR.com
Iovance Biotherapeutics Stock Is Trending Friday: What's Going On? - Benzinga
Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? - TradingView
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Iovance Biotherapeutics grants inducement stock options to 27 new employees - scanx.trade
IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism - Stocktwits
Iovance Shares Rise 12.5% as Analyst Price Targets Lag Behind Rally - TechStock²
Iovance Biotherapeutics Q2 results: Revenue beats estimates, stock hits 52-week high - scanx.trade
Why Iovance Biotherapeutics Stock Hit 52-Week High - TradingView
IOVA Maintained by UBS -- Price Target Raised to $7.00 - GuruFocus
Iovance's Growth Outlook Clouded as Amtagvi Faces Competition Hurdles, UBS Says - marketscreener.com
META_TITLE_QUOTE - Yahoo Finance
Iovance Biotherapeutics, Inc. (IOVA) Latest Stock News & Headlines - Yahoo Finance
IOVA Stock Jumps As Amtagvi Revenue Beat Fuels Bullish Targets - timothysykes.com
Iovance Biotherapeutics (NASDAQ:IOVA) Marks Major Market Shift - Kalkine Media
Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to Buy - Yahoo Finance
Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor Updates (IOVA) - Seeking Alpha
UBS raises Iovance Biotherapeutics stock price target on revenue beat By Investing.com - Investing.com Canada
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month HighWhat's Next? - MarketBeat
IOVA Stock Hits New 52-Week High As Shares Jump 14% — What Drove The Rally? - TradingView
Iovance Biotherapeutics Rallies as Strong Amtagvi Sales Keep Post-Earnings Momentum Alive - Moomoo
Iovance Biotherapeutics, Inc., Qingdao Sino-Cell Biomedicine Co., Ltd., Grit Biotechnologies, Shanghai Juncell Therapeutics, Curacell Holding Ab, Ksq Therapeutics, Sapphire Biotech, Beijing Sali Biopharmaceutical Co., Ltd. Provide Updates on Til Therapy C - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
TIL Therapy Clinical Trial Pipeline Appears Robust With 17+ - GlobeNewswire
IOVA Stock Climbs As Amtagvi Sales Crush Q2 Expectations - timothysykes.com
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 11% Following Analyst Upgrade - MarketBeat
Iovance (IOVA) Market: Closes 8.25% Higher at $7.61 for the Current Session; Chart View: the Near-Term Reference Band Stretches From $7.23 to $7.99 on the DayGamma Squeeze - Vinanet
Iovance Biotherapeutics (IOVA) Earnings Put Its Valuation Back In Focus - Sahm
Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today? - Yahoo Finance
IOVA Maintained by Mizuho -- Price Target Raised to $11.00 - GuruFocus
Iovance Biotherapeutics (NASDAQ:IOVA) Given New $11.00 Price Target at Mizuho - MarketBeat
Rice Hall James & Associates LLC Acquires Shares of 1,539,840 Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits
Mizuho Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $11 - Moomoo
IOVA Stock Price, Quote & Chart - ChartMill
Iovance Biotherapeutics Inc : Baird Assumes C - Moomoo
GSA Capital Partners LLP Buys New Holdings in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Bank of America Corp DE Sells 5,787,694 Shares of Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026 - The Cryptonomist
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance? - Yahoo Finance
Iovance (IOVA) Q2 2026 Earnings Call Transcript - AOL.com
IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Chart - ChartMill
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month HighHere's What Happened - MarketBeat
Iovance Biotherapeutics stock hits 52-week high at 6.94 USD By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics (IOVA) Surges 7% as Biotech Sentiment StrengthensBuyback Factor - Vinanet
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):